Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00983749 · ClinicalTrials.gov registry record · Phase 1
Safety Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke
A Phase 1 study of Stroke, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 3
- Study locations
NCT00983749: Completed Phase 1 study of Stroke, sponsored by University of California, San Diego.
NCT00983749 is a Phase 1 study of Stroke that has completed, run by University of California, San Diego. The registered enrollment target is 23 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00983749, a Phase 1 study of Stroke, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine if external counterpulsation (ECP) is feasible to perform, tolerable, and safe as a treatment for patients with acute ischemic stroke (i.e., a blockage of one of the arteries supplying a part of the brain), and to assess what type of effect it might have on 1) the velocity of blood flow in the arteries supplying the brain and 2) stroke symptoms. The hypothesis of the study is that ECP will be feasible and safe to perform, and will be tolerable for patients with acute ischemic stroke at pressures that increase the velocity of arterial blood flow to the brain.
Primary Outcome
The first primary outcome measure was tolerability and feasibility. Tolerance was defined as the absence of any indications to stop the procedure or reduce the pressure to a non-therapeutic level. Feasibility was defined in the full-pressure group as the sustained (at least 30 minutes) tolerance of any pressure capable of causing a 15% augmentation of MFV in 90% of subjects, and defined in the sham-pressure group as the sustained tolerance of the sham pressure in all subjects.
Conditions Studied
Interventions
- DEVICE Full-pressure ECP
- DEVICE Sham-pressure ECP
Study Locations (3)
California
- UCLA Medical Center - Los Angeles
- UCSD Medical Center - San Diego
Alabama
- University of Alabama Hospital - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
What the finished NCT00983749 record still lists
NCT00983749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Full-pressure ECP is the first listed.
NCT00983749 reports a single indexed study location in California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00983749 about?
NCT00983749 is a clinical study titled "Safety Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke". The purpose of this study is to determine if external counterpulsation (ECP) is feasible to perform, tolerable, and safe as a treatment for patients with acute ischemic stroke (i.e., a blockage of one of the arteries supplying a part of the brain), and to assess what type of effect it might have on ...
What is the current status of trial NCT00983749?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2009-12. Estimated completion is 2013-07.
What conditions does trial NCT00983749 study?
This clinical trial studies the following conditions: Stroke.
What interventions are being tested in trial NCT00983749?
The interventions under investigation include: Full-pressure ECP (DEVICE), Sham-pressure ECP (DEVICE).
Who is sponsoring clinical trial NCT00983749?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00983749 being conducted?
This trial has 3 study locations across Alabama, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00983749's enrollment target sits among peer trials
23 347th of 454 higher than 104 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
RECRUITING · Phase 1
-
Hybrid Robot+FES Stroke Rehabilitation
RECRUITING · Phase 1
-
Vibrotactile Stimulation for Upper-Extremity Stroke Rehabilitation
RECRUITING · Phase 1
-
Facilitating Neuroplastic Changes of Acute Stroke Survivors
RECRUITING · Phase 1
-
Identifying Personalized Brain States Predicting Residual Corticospinal Tract Output After Stroke
RECRUITING · Phase 1
-
Accelerated rTMS vs. Sham for Stroke Apathy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia